Pro-Adrenomedullin predicts 10-year all-cause mortality in community-dwelling patients: a prospective cohort study

What Was Tested

This observational study paper looks at Adrenomedullin.

The researchers calculated Cox regression models and area under the receiver operating characteristics curves to assess associations of ProADM with 10-year all-cause mortality.

Why It Was Studied

The researchers evaluated associations of ProADM levels with 10-year mortality in community-dwelling primary care patients with respiratory tract infections.

Who Took Part

The study group was 134 patients.

PubMed indexes the participants as adults, middle-aged adults, older adults and people over 80, both men and women.

This is a post-hoc analysis using clinical and biomarker data of 134 primary care patients with respiratory tract infections.

ProADM was measured on admission and after 7 days in batch-analysis. 10-year follow-up data was collected by GP, patient and relative tracing through phone interviews.

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got Adrenomedullin and who got the comparison, which limits bias.

A time span of 7 days appears in the methods.

What Was Measured

The researchers evaluated associations of ProADM levels with 10-year mortality in community-dwelling primary care patients with respiratory tract infections.

Topics PubMed links to this paper include Adrenomedullin, Area Under Curve, Biomarkers, Cause of Death, Independent Living, Kaplan-Meier Estimate and Multivariate Analysis.

The authors tagged it with the keywords 10-year follow-up, Outcome, Primary care and Pro-Adrenomedullin.

What This Means in Plain Language

The paper is a randomized study of Adrenomedullin in 134 patients over 7 days.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2017 (BMC cardiovascular disorders), a journal based in England.

More context: the Adrenomedullin compound page, all human trials.